Reported Sunday, Vir’s Elebsiran And Tobevibart Meet Primary Endpoint In Phase 3 ECLIPSE 1 Hepatitis Delta Trial, 44% Achieve Undetectable Virus Plus ALT Normalization Versus 0% Delayed Treatment
Benzinga Newsdesk 7 hours ago
News
Trial met all Phase 3 endpoints and regimen is well-tolerated with all patients completing 48 weeks of treatment100% of patients achieved virologic response at Week 24 with 79% of patients reaching undetectable virus
- Trial met all Phase 3 endpoints and regimen is well-tolerated with all patients completing 48 weeks of treatment
- 100% of patients achieved virologic response at Week 24 with 79% of patients reaching undetectable virus (as defined by HDV RNA TND) at Week 48
- Comprehensive regulatory filing package planned for U.S. FDA submission mid-2027